Sign In
Buy SYK
$295.00
+1.70 (+0.580%)
At Close: Jun 03, 2026
Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result
11:18am, Friday, 03'rd Nov 2023
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.
Stryker tightens profit forecast on steady demand for its medical devices
05:18pm, Thursday, 02'nd Nov 2023
Stryker Corp on Thursday raised the lower end of its full-year profit forecast as the medtech company sees steady demand for its medical and surgical devices from a post-pandemic pick-up in volumes of
Stay Ahead of the Game With Stryker (SYK) Q3 Earnings: Wall Street's Insights on Key Metrics
09:46am, Wednesday, 01'st Nov 2023
Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?
09:01am, Tuesday, 31'st Oct 2023
Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
BAX vs. SYK: Which Stock Is the Better Value Option?
12:47pm, Monday, 30'th Oct 2023
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value inves
Stryker (SYK) Reports Next Week: Wall Street Expects Earnings Growth
11:20am, Thursday, 26'th Oct 2023
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Stryker (SYK) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Tuesday, 24'th Oct 2023
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Value Deepens for Medtech Stocks: Reversal Imminent
10:21am, Monday, 23'rd Oct 2023
Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
11:32am, Tuesday, 17'th Oct 2023
AbbVie is a high-yield dividend stock that packs a punch. Stryker is a well-rounded business.
Stryker: Don't Buy This Dividend Champion (Yet)
10:32am, Friday, 13'th Oct 2023
Stryker's dividend is covered by both adjusted diluted EPS and free cash flow, which should bode well for future dividend growth. The company's dedication to research and development supports its stro
5 Medical Product Stocks to Buy Amid Industry Recovery
09:46am, Thursday, 12'th Oct 2023
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-pois
What other industries could weight loss drugs disrupt?
07:10pm, Wednesday, 11'th Oct 2023
Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
To Dodge Russian Missiles, Ukraine's U.S.-Made Stryker Fighting Vehicles Dodge And Weave. It's A Tactic From 1973.
10:50pm, Saturday, 07'th Oct 2023
A Sagger drill still works at times, and especially in a vehicle as maneuverable as a Stryker is.
Both Wall Street and food companies are overreacting to weight-loss drugs, say Herb Greenberg
08:51pm, Thursday, 05'th Oct 2023
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
09:01am, Wednesday, 04'th Oct 2023
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
